Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167729 | 1.00 | GSR (0.44) | GSRUSP2SLCO1B1PDE4ARNPEP | |
| SCHEMBL1168594 | 1.00 | GSR (0.44) | GSRUSP2SLCO1B1PDE4ARNPEP | |
| SCHEMBL7614414 | 0.97 | GSR (0.44) | GSRUSP2SLCO1B1PDE4ARNPEP | |
| SCHEMBL1168214 | 0.86 | GSR (0.38) | GSRUSP2SLCO1B1GNAI3GNAO1 | |
| SCHEMBL1234805 | 0.86 | GSR (0.38) | GSRUSP2SLCO1B1GNAI3GNAO1 | |
| SCHEMBL1168908 | 0.85 | GSR (0.42) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL17843610 | 0.82 | GSR (0.48) | GSRRNPEPLMNAGNAI3GNAO1 | |
| SCHEMBL22209237 | 0.82 | GSR (0.48) | GSRRNPEPLMNAGNAI3GNAO1 | |
| SCHEMBL1168273 | 0.82 | GSR (0.42) | GSRUSP2RNPEPGNAI3GNAO1 | |
| SCHEMBL1168280 | 0.82 | GSR (0.42) | GSRUSP2SLCO1B1PDE4ARNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10732186-B2 | Methods and reagents for the assessment of gestational diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | claimed |
| EP-2348050-B1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | claimed |
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | claimed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | US | claimed |
| EP-1898930-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | Dynamis Therapeutics, Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20070021357-A1 | Treatment of inflammatory conditions | DYNAMIS THERAPEUTICS, INC. | 2007-01-25 | — | — | US | claimed |
| WO-2006138609-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060247155-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | BROWN TRUMAN R | 2006-11-02 | — | — | US | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-0271996-B1 | IMMUNOCHEMICAL METHOD FOR ASSAYING STABLE GLYCOSYLATED HEMOGLOBIN | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-01-29 | — | — | EP | claimed |
| US-4778752-A | MONOCLONAL ANTIBODIES BINDING REDUCED GLYCOSYLATED PROTEINS; BLOOD ANALYSIS OF DIABETICS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1988-10-18 | — | — | US | claimed |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-02-06 | — | — | US | disclosed |
| US-11866506-B2 | Anti-CD59 antibodies | MELLITUS, LLC (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023225178-A1 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | MELLITUS, LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2022241236-A2 | METHODS AND REAGENTS FOR PROTEIN ANALYSIS | MELLITUS, LLC (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-05-26 | — | — | US | disclosed |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210284751-A1 | METHODS AND ANTIBODIES FOR DIABETES-RELATED APPLICATIONS | HALPERIN, JOSE | 2021-09-16 | — | — | US | disclosed |
| EP-2673293-B1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | HARVARD COLLEGE (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10732186-B2 | Methods and reagents for the assessment of gestational diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3620793-A1 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | President And Fellows Of Harvard College (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3612625-A1 | METHODS AND ANTIBODIES FOR DIABETES-RELATED APPLICATIONS | Mellitus, LLC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3077815-B1 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | HARVARD COLLEGE (US) | 2019-07-17 | — | — | EP | disclosed |
| CN-109917125-A | For assessing the method and reagent of gestational diabetes mellitus | 哈佛大学董事会 | 2019-06-21 | — | — | CN | disclosed |
| US-10309973-B2 | Surrogates of post-translationally modified proteins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-06-04 | — | — | US | disclosed |
| CN-105934671-B | Methods and reagents for assessing gestational diabetes | 哈佛大学董事会 | 2019-04-19 | — | — | CN | disclosed |
| WO-2018195008-A1 | METHODS AND ANTIBODIES FOR DIABETES-RELATED APPLICATIONS | MELLITUS, LLC (US) | 2018-10-25 | — | — | WO | disclosed |
| EP-2348050-B1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170199201-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170108505-A2 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170023589-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | HARVARD COLLEGE (US) | 2017-01-26 | — | — | US | disclosed |
| US-20160299150-A1 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | HARVARD COLLEGE (US) | 2016-10-13 | — | — | US | disclosed |
| EP-3077815-A1 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | President and Fellows of Harvard College (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-105934671-A | Methods and reagents for assessing gestational diabetes | 哈佛大学董事会 | 2016-09-07 | — | — | CN | disclosed |
| US-9417248-B2 | Surrogates of post-translationally modified proteins and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-16 | — | — | US | disclosed |
| WO-2015084994-A1 | METHODS AND REAGENTS FOR THE ASSESSMENT OF GESTATIONAL DIABETES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-1021175-B1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140322723-A1 | DIABETES DIAGNOSIS THROUGH THE DETECTION OF GLYCATED PROTEINS IN URINE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-10-30 | — | — | US | disclosed |
| US-20140024056-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2673293-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | President and Fellows of Harvard College (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013078122-A1 | DIABETES DIAGNOSIS THROUGH THE DETECTION OF GLYCATED PROTEINS IN URINE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-30 | — | — | WO | disclosed |
| US-8431527-B2 | Methods for alleviating deleterious effects of 3-deoxyglucosone | FOX CHASE CANCER CENTER (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012109538-A2 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110034522-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | THE INSTITUTE FOR CANCER RESEARCH | 2011-02-10 | — | — | US | disclosed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7622117-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7615528-B2 | Methods for alleviating deleterious effects of 3-deoxyglucosone | FOX CHASE CANCER CENTER (US) | 2009-11-10 | — | — | US | disclosed |
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008137165-A1 | ANTI-GLYCATED CD59 ANTIBODIES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1126856-A4 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008045272-A2 | COMPOSITIONS AND METHODS FOR SKIN LIGHTENING | DYNAMIS THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| EP-1898930-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | Dynamis Therapeutics, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070270335-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | BROWN TRUMAN R | 2007-11-22 | — | — | US | disclosed |
| WO-2007117394-A2 | COMPOSITIONS AND METHODS RELATED TO FRUCTOSAMINE-3-KINASE INHIBITORS | DYNAMIS THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070021357-A1 | Treatment of inflammatory conditions | DYNAMIS THERAPEUTICS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006138609-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060247155-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | BROWN TRUMAN R | 2006-11-02 | — | — | US | disclosed |
| US-20060241023-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | BROWN TRUMAN R | 2006-10-26 | — | — | US | disclosed |
| US-7071298-B2 | Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins | FOX CHASE CANCER CENTER (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-20040191241-A1 | Antigen with haptenic mannitol epitopes and a method of preparing antibodies specific to D-mannitol | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | disclosed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1085885-B1 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CT (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-1021175-A4 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CT (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020111291-A1 | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention | THE INSTITUTE FOR CANCER RESEARCH | 2002-08-15 | — | — | US | disclosed |
| CN-1331599-A | Compounds and their use for treating diabetic complications | FOX CHASE CANCER CT (US) | 2002-01-16 | — | — | CN | disclosed |
| EP-1085885-A4 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CT (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1126856-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1085885-A2 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CENTER (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000024405-A9 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-1021175-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000024405-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-05-04 | — | — | WO | disclosed |
| WO-1999064561-A2 | METHOD FOR ASSESSING A DIABETIC'S RISK OF EXPERIENCING A DIABETES-ASSOCIATED PATHOLOGIC CONDITION | FOX CHASE CANCER CENTER (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998033492-A1 | COMPOUNDS AND METHODS FOR THERAPEUTIC INTERVENTION IN PREVENTING DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 1998-08-06 | — | — | WO | disclosed |
| EP-0487621-B1 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS | UNIV NORTHWESTERN (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5494791-A | DETECTING AND MONITORING CARDIOVASCULAR DISORDERS AND DIABETES | EXOCELL, INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5484735-A | Immunoassay of glycosylated proteins employing antibody directed to reductively glycosylated N-terminal amino acids | NORTHWESTERN UNIVERSITY (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0358739-B1 | MONOCLONAL ANTIBODIES AGAINST GLYCATED ALBUMIN, HYBRID CELL LINES PRODUCING THESE ANTIBODIES, AND USE THEREOF | EXOCELL INC (US) | 1995-07-19 | — | — | EP | disclosed |
| EP-0444787-B1 | Monoclonal antibodies against non-A 1C glycated hemoglobin | EXOCELL INC (US) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994029722-A1 | TWO-PHASE OPTICAL ASSAY METHOD AND APPARATUS | CHRONOMED, INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994000592-A1 | MONOCLONAL ANTIBODIES AGAINST GLYCATED LOW DENSITY LIPOPROTEIN | EXOCELL, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5223392-A | Monitoring glucose concentration of blood; diabetes | EXOCELL, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0312540-B1 | MONOCLONAL ANTIBODIES TO UNREDUCED, NONENZYMATICALLY-GLYCATED PROTEINS | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5183739-A | Hybridoma which produces antibody binds to an epitope on glycohemoglobin comprising epsilon-d-fructosyllysine is useful for diagnosis of diseases | EXOCELL, INC. (US) | 1993-02-02 | — | — | US | disclosed |
| US-5169937-A | Diagnostic tests; converting stable glucohemoglobin to glucitollysinehemoglobin by reacting a blood sample with phthalic acid followed by a reducing agent; diabetes | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0487621-A4 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS | — | 1992-06-24 | — | — | EP | disclosed |
| EP-0487621-A1 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS. | UNIV NORTHWESTERN (US) | 1992-06-03 | — | — | EP | disclosed |
| EP-0271996-B1 | IMMUNOCHEMICAL METHOD FOR ASSAYING STABLE GLYCOSYLATED HEMOGLOBIN | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-01-29 | — | — | EP | disclosed |
| EP-0444787-A2 | Monoclonal antibodies against non-A 1C glycated hemoglobin | EXOCELL, INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0358739-A4 | MONOCLONAL ANTIBODIES AGAINST GLYCATED ALBUMIN, HYBRID CELL LINES PRODUCING THESE ANTIBODIES, AND USE THEREFORE | — | 1991-07-03 | — | — | EP | disclosed |
| WO-1991002978-A1 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS | NORTHWESTERN UNIVERSITY (US) | 1991-03-07 | — | — | WO | disclosed |
| EP-0358739-A1 | MONOCLONAL ANTIBODIES AGAINST GLYCATED ALBUMIN, HYBRID CELL LINES PRODUCING THESE ANTIBODIES, AND USE THEREFORE. | EXOCELL INC (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0312540-A4 | MONOCLONAL ANTIBODIES TO UNREDUCED, NONENZYMATICALLY-GLYCATED PROTEINS. | UNIV MINNESOTA (US) | 1990-01-08 | — | — | EP | disclosed |
| US-4876188-A | REMOVING LABILE FORM WITH PHTHALIC ACID, REDUCING WITH BOROHYD RIDE TO FORM GLUCITOLLYSINE-HEMOGLOBIN, QUANTIFYING BY REACTIN G WITH ANTIBODY | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-10-24 | — | — | US | disclosed |
| WO-1989006798-A1 | MONOCLONAL ANTIBODIES AGAINST GLYCATED ALBUMIN, HYBRID CELL LINES PRODUCING THESE ANTIBODIES, AND USE THEREFORE | EXOCELL, INC. (US) | 1989-07-27 | — | — | WO | disclosed |
| US-4837170-A | FOR DIAGNOSIS OF DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0312540-A1 | MONOCLONAL ANTIBODIES TO UNREDUCED, NONENZYMATICALLY-GLYCATED PROTEINS. | UNIV MINNESOTA (US) | 1989-04-26 | — | — | EP | disclosed |
| US-4797473-A | IMMUNIZING MAMMALS, HYBRIDOMAS, CLONING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-01-10 | — | — | US | disclosed |
| US-4778752-A | MONOCLONAL ANTIBODIES BINDING REDUCED GLYCOSYLATED PROTEINS; BLOOD ANALYSIS OF DIABETICS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0271996-A1 | Immunochemical method for assaying stable glycosylated hemoglobin | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1988-06-22 | — | — | EP | disclosed |
| WO-1988000346-A1 | MONOCLONAL ANTIBODIES TO UNREDUCED, NONENZYMATICALLY-GLYCATED PROTEINS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-01-14 | — | — | WO | disclosed |
| EP-0230934-A2 | Monoclonal antibody, measuring method of glucosylated protein by utilizing the monoclonal antibody, and kit therefor. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-08-05 | — | — | EP | disclosed |
| EP-0230934-A2 | Monoclonal antibody, measuring method of glucosylated protein by utilizing the monoclonal antibody, and kit therefor. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034522-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | AGER, ALDOA, FBP1 | GSR 295/4885USP2 2446/4885SLCO1B1 2995/4885 |
| US-20220162333-A1 | GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF | CD59, SIGLEC9, CD209 | GSR 3006/4885USP2 4657/4885SLCO1B1 980/4885 |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | GSR 2465/4885USP2 3586/4885SLCO1B1 3313/4885 |
| US-11891448-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | GSR 3006/4885USP2 4657/4885SLCO1B1 980/4885 |
| US-20020111291-A1 | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention | FANCF, FANCI, AGER | GSR 1007/4885USP2 2395/4885SLCO1B1 1129/4885 |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | FN3K, ROS1, FN3KRP | GSR 712/4885USP2 3512/4885SLCO1B1 3841/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | GSR 1409/4885USP2 2812/4885SLCO1B1 784/4885 |
| US-11161910-B2 | Glycated CD59 peptides, their preparation, and uses thereof | CD59, SIGLEC9, CD209 | GSR 3006/4885USP2 4657/4885SLCO1B1 980/4885 |
| US-20140024056-A1 | SURROGATES OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF | CD59, SIGLEC9, CD209 | GSR 2586/4885USP2 2725/4885SLCO1B1 2540/4885 |
| US-20210284751-A1 | METHODS AND ANTIBODIES FOR DIABETES-RELATED APPLICATIONS | CD59, SIGLEC9, AGER | GSR 2065/4885USP2 3710/4885SLCO1B1 923/4885 |
| US-20060247155-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | AGER, ALDOA, FBP1 | GSR 314/4885USP2 2496/4885SLCO1B1 2941/4885 |
| US-20070270335-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | AGER, ALDOA, FBP1 | GSR 295/4885USP2 2446/4885SLCO1B1 2995/4885 |
| US-10309973-B2 | Surrogates of post-translationally modified proteins and uses thereof | CD59, SIGLEC9, CD209 | GSR 2586/4885USP2 2725/4885SLCO1B1 2540/4885 |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DPM1, G6PD, UGGT1 | GSR 1409/4885USP2 2812/4885SLCO1B1 784/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | GSR 1409/4885USP2 2812/4885SLCO1B1 784/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | GSR 138/4885USP2 2064/4885SLCO1B1 4169/4885 |
| US-20060241023-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | AGER, ALDOA, FBP1 | GSR 297/4885USP2 2621/4885SLCO1B1 2814/4885 |
| US-11866506-B2 | Anti-CD59 antibodies | CD59, SIGLEC9, CD58 | GSR 2258/4885USP2 3935/4885SLCO1B1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.